The Journal of Nutritional Biochemistry
Volume 20, Issue 12 , Pages 927-939 , December 2009

Beyond blood lipids: phytosterols, statins and omega-3 polyunsaturated fatty acid therapy for hyperlipidemia

  • Michelle A. Micallef

      Affiliations

    • Nutraceuticals Research Group, School of Biomedical Sciences, The University of Newcastle, Callaghan, NSW 2308, Australia
    • ,
  • Manohar L. Garg

      Affiliations

    • Nutraceuticals Research Group, School of Biomedical Sciences, The University of Newcastle, Callaghan, NSW 2308, Australia
    • Hunter Medical Research Institute, John Hunter Hospital, New Lambton, NSW 2310, Australia
    • Corresponding Author InformationCorresponding author. Nutraceuticals Research Group, School of Biomedical Sciences, The University of Newcastle, Callaghan, NSW 2308, Australia. Tel.: +61 02 4921 5647; fax: +61 02 4921 2028.

Received 31 March 2009 ,Revised 26 May 2009 ,Accepted 19 June 2009.

References 

  1. Kolovou GD, Anagnostopoulou KK, Cokkinos DV. Pathophysiology of dyslipidaemia in the metabolic syndrome. Postgrad Med J. 2005;81(956):358–366
  2. Bernard J. Free fatty acid receptor family: novel targets for the treatment of diabetes and dyslipidemia. Curr Opin Investig Drugs. 2008;9(10):1078–1083
  3. Funatsu T, et al. Prolonged inhibition of cholesterol synthesis by atorvastatin inhibits apo B-100 and triglyceride secretion from HepG2 cells. Atherosclerosis. 2001;157(1):107–115
  4. Gordon T, Kannel WB. Premature mortality from coronary heart disease. The Framingham Study. JAMA. 1971;215(10):1617–1625
  5. Iso H, et al. Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial. N Engl J Med. 1989;320(14):904–910
  6. Holvoet P, et al. The relationship between oxidized LDL and other cardiovascular risk factors and subclinical CVD in different ethnic groups: The Multi-Ethnic Study of Atherosclerosis (MESA). Atherosclerosis. 2006;
  7. NHFA . Lipid management guidelines—2001. National Heart Foundation of Australia, The Cardiac Society of Australia and New Zealand. Med J Aust. 2001;175(Suppl):S57–S85
  8. Genest J, et al. Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: summary of the 2003 update. CMAJ. 2003;169(9):921–924
  9. NCEP . Expert Panel of Detection Evaluation and Treatment of High Blood Cholesterol in Adults. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) (Adult Treatment Pannel III). JAMA. 2001;285:2486–2497
  10. Expert panel on Detection, E., and Treatment of High Blood Cholesterol in Adults . Executive summary of the Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;2486–2497
  11. Esteve E, Ricart W, Fernandez-Real JM. Dyslipidemia and inflammation: an evolutionary conserved mechanism. Clin Nutr. 2005;24(1):16–31
  12. Gau GT, Wright RS. Pathophysiology, diagnosis, and management of dyslipidemia. Curr Probl Cardiol. 2006;31(7):445–486
  13. Leibovitz E, et al. Beyond guidelines: achieving the optimum in LDL cholesterol control. Curr Opin Lipidol. 2005;16(6):635–639
  14. Nies LK, et al. Complementary and alternative therapies for the management of dyslipidemia. Ann Pharmacother. 2006;40:1984–1992
  15. Brufau G, Canela MA, Rafecas M. Phytosterols: physiologic and metabolic aspects related to cholesterol-lowering properties. Nutr Res. 2008;28(4):217–225
  16. Tikkanen MJ. Plant sterols and stanols. Handb Exp Pharmacol. 2005;(170):215–230
  17. Clifton P. Plant sterol and stanols—comparison and contrasts. Sterols versus stanols in cholesterol-lowering: is there a difference?. Atheroscler Suppl. 2002;3(3):5–9
  18. Moreau RA, Whitaker BD, Hicks KB. Phytosterols, phytostanols, and their conjugates in foods: structural diversity, quantitative analysis, and health-promoting uses. Prog Lipid Res. 2002;41(6):457–500
  19. Weihrauch JL, Gardner JM. Sterol content of foods of plant origin. J Am Diet Assoc. 1978;73(1):39–47
  20. Ostlund RE. Phytosterols in human nutrition. Annu Rev Nutr. 2002;22:533–549
  21. Phillips KM, Ruggio DM, Ashraf-Khorassani M. Phytosterol composition of nuts and seeds commonly consumed in the United States. J Agric Food Chem. 2005;53(24):9436–9445
  22. Connor WE. Dietary sterols: their relationship to atherosclerosis. J Am Diet Assoc. 1968;52(3):202–208
  23. Nair PP, et al. Diet, nutrition intake, and metabolism in populations at high and low risk for colon cancer. Dietary cholesterol, beta-sitosterol, and stigmasterol. Am J Clin Nutr. 1984;40(4 Suppl):927–930
  24. Sanders DJ, et al. The safety evaluation of phytosterol esters: Part 6. The comparative absorption and tissue distribution of phytosterols in the rat. Food Chem Toxicol. 2000;38(6):485–491
  25. Salen G, Ahrens EH, Grundy SM. Metabolism of beta-sitosterol in man. J Clin Invest. 1970;49(5):952–967
  26. Heinemann T, Axtmann G, von Bergmann K. Comparison of intestinal absorption of cholesterol with different plant sterols in man. Eur J Clin Invest. 1993;23(12):827–831
  27. Andersson S, et al. Intake of dietary sterols is inversely related serum cholesterol concentration in men and women in the EPIC Norfolk population: a cross-sectional study. Eur J Clin Nutr. 2004;58:1378–1385
  28. Altmann SW, et al. Niemann–Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Science. 2004;303(5661):1201–1204
  29. Yu L, et al. Disruption of Abcg5 and Abcg8 in mice reveals their crucial role in biliary cholesterol secretion. Proc Natl Acad Sci U S A. 2002;99(25):16237–16242
  30. Sudhop T, et al. Comparison of the hepatic clearances of campesterol, sitosterol, and cholesterol in healthy subjects suggests that efflux transporters controlling intestinal sterol absorption also regulate biliary secretion. Gut. 2002;51(6):860–863
  31. Von Bergmann K, Sudhop T, Lutjohann D. Cholesterol and plant sterol absorption: recent insights. Am J Cardiol. 2005;96(1A):10D–14D
  32. Hallikainen M, et al. Short-term LDL cholesterol-lowering efficacy of plant stanol esters. BMC Cardiovasc Disord. 2002;2:14
  33. Ikeda I, Tanabe Y, Sugano M. Effects of sitosterol and sitostanol on micellar solubility of cholesterol. J Nutr Sci Vitaminol (Tokyo). 1989;35(4):361–369
  34. Subbiah MT, Kottke BA, Carlo IA. Uptake of campesterol in pigeon intestine. Biochim Biophys Acta. 1971;249(2):643–646
  35. Ling WH, Jones PJ. Dietary phytosterols: a review of metabolism, benefits and side effects. Life Sci. 1995;57(3):195–206
  36. Jones PJ, et al. Modulation of plasma lipid levels and cholesterol kinetics by phytosterol versus phytostanol esters. J Lipid Res. 2000;41:697–705
  37. Garti N, Avrahami M, Aserin A. Improved solubilization of celecoxib in U-type nonionic microemulsions and their structural transitions with progressive aqueous dilution. J Colloid Interface Sci. 2006;299(1):352–365
  38. Plat J, Mensink RP. Increased intestinal ABCA1 expression contributes to the decrease in cholesterol absorption after plant stanol consumption. FASEB J. 2002;16(10):1248–1253
  39. Plat J, Mensink RP. Plant stanol and sterol esters in the control of blood cholesterol levels: mechanism and safety aspects. Am J Cardiol. 2005;96(1A):15D–22D
  40. Field FJ, Mathur SN. Beta-sitosterol: esterification by intestinal acylcoenzyme A: cholesterol acyltransferase (ACAT) and its effect on cholesterol esterification. J Lipid Res. 1983;24(4):409–417
  41. Krauss RM, et al. AHA dietary guidelines. Circulation. 2000;102:2284–2299
  42. Gylling H, Miettinen TA. Effects of inhibiting cholesterol absorption and synthesis on cholesterol and lipoprotein metabolism in hypercholesterolemic non-insulin-dependent diabetic men. J Lipid Res. 1996;37(8):1776–1785
  43. Valkema AJ. The influence of phytosterols on the absorption of cholesterol. Acta Physiol Pharmacol Neerl. 1955;4(2):291–292
  44. Eisenberg D. Naturally available oils contain phytosterols that affect cholesterol absorption. Curr Atheroscler Rep. 2003;5(1):55
  45. Shin MJ, et al. Micellar phytosterols effectively reduce cholesterol absorption at low doses. Ann Nutr Metab. 2005;49(5):346–351
  46. Clifton PM, et al. Dose–response effects of different plant sterol sources in fat spreads on serum lipids and C-reactive protein and on the kinetic behavior of serum plant sterols. Eur J Clin Nutr. 2007;1–10
  47. Amundsen AL, et al. Long-term compliance and changes in plasma lipids, plant sterols and carotenoids in children and parents with FH consuming plant sterol ester-enriched spread. Eur J Clin Nutr. 2004;58(12):1612–1620
  48. IAS executive board . In: Harmonized Clinical Guidelines on the Prevention of Atherosclerotic Vascular Disease. Hamburg, Germany: International Atherosclerosis Society; 2003;p. 1–28
  49. NHFA , CSANZ . Position statement on lipid management. Heart Lung Circ. 2005;14:275–291
  50. Nestel P. Cholesterol-lowering with plant sterols. Med J Aust. 2002;176:S122
  51. Wolfs M, et al. Effectiveness of customary use of phytosterol/-stanol enriched margarines on blood cholesterol lowering. Food Chem Toxicol. 2006;44:1682–1688
  52. Madsen MB, Jensen AM, Schmidt EB. The effect of a combination of plant sterol-enriched foods in mildly hypercholesterolemic subjects. Clin Nutr. 2007;26(6):792–798
  53. Jones PJ, Abumweis SS. Phytosterols as functional food ingredients: linkages to cardiovascular disease and cancer. Curr Opin Clin Nutr Metab Care. 2009;12(2):147–151
  54. Goldberg AC, et al. Effect of plant stanol tablets on low-density lipoprotein cholesterol lowering in patients on statin drugs. Am J Cardiol. 2006;97(3):376–379
  55. Law M. Plant sterol and stanol margarines and health. BMJ. 2000;320(7238):861–864
  56. Thompson G, O'Neill F, Seed M. Why some patients respond poorly to statins and how this might be remedied. Eur Heart J. 2002;23:200–206
  57. Nestel P, Cehum M, Pomeroy S. Cholesterol lowering effects of plant sterol esters and non-esterified stanols in margarine, butter and low fat foods. Eur J Clin Nutr. 2001;55:1084–1090
  58. Weststrate JA, Meijer GW. Plant sterol-enriched margarines and reduction of plasma total- and LDL-cholesterol concentrations in normocholesterolaemic and mildly hypercholesterolaemic subjects. Eur J Clin Nutr. 1998;52(5):334–343
  59. Gylling H, Miettinen TA. Cholesterol reduction by different plant stanol mixtures and with variable fat intake. Metabolism. 1999;48(5):575–580
  60. Moruisi KG, Oosthuizen W, Opperman AM. Phytosterols/stanols lower cholesterol concentrations in familial hypercholesterolemic subjects: a systematic review with meta-analysis. J Am Coll Nutr. 2006;25(1):41–48
  61. Hendriks HF, et al. Safety of long-term consumption of plant sterol esters-enriched spread. Eur J Clin Nutr. 2003;57(5):681–692
  62. Noakes M, Clifton P, Ntanios F. An increase in dietary carotenoids when consuming plant sterols or stanol esters is effective in maintaining plasma carotenoids concentrations. Am J Clin Nutr. 2002;75:79–86
  63. Clifton PM, et al. High dietary intake of phytosterol esters decreases carotenoids and increases plasma plant sterol levels with no additional cholesterol lowering. J Lipid Res. 2004;45(8):1493–1499
  64. Colgan HA, et al. Increased intake of fruit and vegetables and a low-fat diet, with and without low-fat plant sterol-enriched spread consumption: effects on plasma lipoprotein and carotenoid metabolism. J Hum Nutr Diet. 2004;17(6):561–569
  65. Sanchez-Muniz FJ, et al. Serum lipid and antioxidant responses in hypercholesterolemic men and women receiving plant sterol esters vary by apolipoprotein E genotype. J Nutr. 2009;139(1):13–19
  66. de Jong N, et al. Exposure and effectiveness of phytosterol/-stanol-enriched margarines. Eur J Clin Nutr. 2007;61(12):1407–1415
  67. Noakes M, et al. Plant sterol ester-enriched milk and yoghurt effectively reduce serum cholesterol in modestly hypercholesterolemic subjects. Eur J Nutr. 2005;44(4):214–222
  68. Nestel P. Effects of fish oils and fish on cardiovascular disease. Curr Atheroscler Rep. 2001;3(1):68–73
  69. Clifton PM, et al. Cholesterol-lowering effects of plant sterols esters differ in milk, yoghurt, bread and cereal. Eur J Clin Nutr. 2004;58:503–509
  70. Takeshita M, et al. Phytosterols dissolved in diacylglycerol oil reinforce the cholesterol-lowering effect of low-dose pravastatin treatment. Nutr Metab Cardiovasc Dis. 2008;18(7):483–491
  71. Simons LA. Additive effect of plant sterol-ester margarine and cerivastatin in lowering low-density lipoprotein cholesterol in primary hypercholesterolemia. Am J Cardiol. 2002;90(7):737–740
  72. Robert W. The rule of 5 and the rule of 7 in lipid-lowering by statin drugs. Am J Cardiol. 1997;80:106–107
  73. Neil HA, Meijer GW, Roe LS. Randomised controlled trial of use by hypercholesterolaemic patients of a vegetable oil sterol-enriched fat spread. Atherosclerosis. 2001;156(2):329–337
  74. Gylling H, Radhakrishnan R, Miettinen TA. Reduction of serum cholesterol in postmenopausal women with previous myocardial infarction and cholesterol malabsorption induced by dietary sitostanol ester margarine: women and dietary sitostanol. Circulation. 1997;96(12):4226–4231
  75. Miettinen TA, Strandberg TE, Gylling H. Noncholesterol sterols and cholesterol lowering by long-term simvastatin treatment in coronary patients: relation to basal serum cholestanol. Arterioscler Thromb Vasc Biol. 2000;20(5):1340–1346
  76. Vanhanen H. Cholesterol malabsorption caused by sitostanol ester feeding and neomycin in pravastatin-treated hypercholesterolaemic patients. Eur J Clin Pharmacol. 1994;47(2):169–176
  77. Patch CS, et al. The use of novel foods enriched with long-chain n-3 fatty acids to increase dietary intake: a comparison of methodologies assessing nutrient intake. J Am Diet Assoc. 2005;105(12):1918–1926
  78. Keys A. Diet and the epidemiology of coronary heart disease. J Am Med Assoc. 1957;164(17):1912–1919
  79. Miettinen TA, Gylling H. Effect of statins on noncholesterol sterol levels: implications for use of plant stanols and sterols. Am J Cardiol. 2005;96(1A):40D–46D
  80. Seo T, Blaner WS, Deckelbaum RJ. Omega-3 fatty acids: molecular approaches to optimal biological outcomes. Curr Op Lipidiol. 2005;16:11–18
  81. Yaqoob P. Fatty acids and the immune system: from basic science to clinical applications. Proc Nutr Soc. 2004;63(1):89–104
  82. Grundy SM, Denke MA. Dietary influences on serum lipids and lipoproteins. J Lipid Res. 1990;31:1149–1172
  83. Miller MR, Nichols PD, Carter CG. n-3 Oil sources for use in aquaculture—alternatives to the unsustainable harvest of wild fish. Nutr Res Rev. 2008;21(2):85–96
  84. Garg ML, et al. Means of delivering recommended levels of long chain n-3 polyunsaturated fatty acids in human diets. J Food Sci. 2006;71(5):R66–R71
  85. Ruxton C. Health benefits of omega-3 fatty acids. Nur Stand. 2004;18(48):38–42
  86. Lombardo YB, Chicco AG. Effects of dietary polyunsaturated n-3 fatty acids on dyslipidemia and insulin resistance in rodents and humans. A review. J Nutr Biochem. 2006;17:1–13
  87. Weintraub MS, et al. Dietary polyunsaturated fats of the W-6 and W-3 series reduce postprandial lipoprotein levels. Chronic and acute effects of fat saturation on postprandial lipoprotein metabolism. J Clin Invest. 1988;82(6):1884–1893
  88. Woodman RJ, et al. Effects of purified eicosapentaenoic and docosahexaenoic acids on glycemic control, blood pressure, and serum lipids in type 2 diabetic patients with treated hypertension. Am J Clin Nutr. 2002;76(5):1007–1015
  89. Nestel PJ, et al. Suppression by diets rich in fish oil of very low density lipoprotein production in man. J Clin Invest. 1984;74(1):82–89
  90. Clarke SD. The multi-dimensional regulation of gene expression by fatty acids: polyunsaturated fats as nutrient sensors. Curr Opin Lipidol. 2004;15(1):13–18
  91. Brown AM, et al. Administration of n-3 fatty acids in the diets of rats or directly to hepatocyte cultures results in different effects on hepatocellular ApoB metabolism and secretion. Arterioscler Thromb Vasc Biol. 1999;19(1):106–114
  92. Davidson MH. Mechanisms for the hypotriglyceridemic effect of marine omega-3 fatty acids. Am J Cardiol. 2006;98(4A):27i–33i
  93. Bruce C, Sharp D, Tall A. Relationship of HDL and coronary heart disease to a common amino acid polymorphism in the cholesteryl ester transfer protein in men with and without hypertriglyceridemia. J Lipid Res. 1998;38:1071–1078
  94. Borggreve S, et al. High plasma cholesteryl ester transfer protein levels may favour reduced incidence of cardiovascular events in men with low triglycerides. Eur Heart J. 2007;
  95. Kang JX, Weylandt KH. Modulation of inflammatory cytokines by omega-3 fatty acids. Subcell Biochem. 2008;49:133–143
  96. James MJ, Gibson RA, Cleland LG. Dietary polyunsaturated fatty acids and inflammatory mediator production. Am J Clin Nutr. 2000;71(1 Suppl):343S–348S
  97. Calder PC. Dietary modification of inflammation with lipids. Proc Nutr Soc. 2002;61(3):345–358
  98. Zhao G, et al. Dietary alpha-linolenic acid inhibits proinflammatory cytokine production by peripheral blood mononuclear cells in hypercholesterolemic subjects. Am J Clin Nutr. 2007;85(2):385–391
  99. von Schacky C. Omega-3 fatty acids and cardiovascular disease. Curr Opin Clin Nutr Metab Care. 2007;10(2):129–135
  100. Mozaffarian D, Rimm EB. Fish intake, contaminants, and human health: evaluating the risks and the benefits. JAMA. 2006;296(15):1885–1899
  101. Hooper L, et al. Risks and benefits of omega 3 fats for mortality, cardiovascular disease, and cancer: systematic review. BMJ. 2006;332(7544):752–760
  102. Yokoyama M, et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet. 2007;369(9567):1090–1098
  103. Ginsberg GL, Toal BF. Quantitative approach for incorporating methylmercury risks and omega-3 fatty acid benefits in developing species-specific fish consumption advice. Environ Health Perspect. 2009;117(2):267–275
  104. Mori TA, et al. Purified eicosapentaenoic and docosahexaenoic acids have differential effects on serum lipids and lipoproteins, LDL particle size, glucose, and insulin in mildly hyperlipidemic men. Am J Clin Nutr. 2000;71(5):1085–1094
  105. Bordin P, Bodamer O, Vaenkatesan S. Effects of fish oil supplementation on apolipoprotein B100 production and lipoprotein metabolism in normolipidaemic males. Eur J Clin Nutr. 1998;52:104–109
  106. Chan DC, et al. Effect of atorvastatin and fish oil on plasma high-sensitivity C-reactive protein concentrations in individuals with visceral obesity. Clin Chem. 2002;48(6 Pt 1):877–883
  107. Grimsgaard S, et al. Highly purified eicosapentaenoic acid and docosahexaenoic acid in humans have similar triacylglycerol-lowering effects but divergent effects on serum fatty acids. Am J Clin Nutr. 1997;66(3):649–659
  108. Harris WS. Fish oils and plasma lipid and lipoprotein metabolism in humans: a critical review. J Lipid Res. 1989;30(6):785–807
  109. Athyros VG, et al. Safety and efficacy of long-term statin-fibrate combinations in patients with refractory familial combined hyperlipidemia. Am J Cardiol. 1997;80(5):608–613
  110. Pauciullo P, et al. Efficacy and safety of a combination of fluvastatin and bezafibrate in patients with mixed hyperlipidaemia (FACT study). Atherosclerosis. 2000;150(2):429–436
  111. Pierce LR, Wysowski DK, Gross TP. Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy. JAMA. 1990;264(1):71–75
  112. Schectman G, Hiatt J. Drug therapy for hypercholesterolemia in patients with cardiovascular disease: factors limiting achievement of lipid goals. Am J Med. 1996;100(2):197–204
  113. Schectman G, Hiatt J. Dose–response characteristics of cholesterol-lowering drug therapies: implications for treatment. Ann Intern Med. 1996;125(12):990–1000
  114. Barter P, Ginsberg HN. Effectiveness of combined statin plus omega-3 fatty acid therapy for mixed dyslipidemia. Am J Cardiol. 2008;102(8):1040–1045
  115. Savelieva I, Camm J. Statins and polyunsaturated fatty acids for treatment of atrial fibrillation. Nat Clin Pract Cardiovasc Med. 2008;5(1):30–41
  116. Davidson MH, et al. Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study. Clin Ther. 2007;29(7):1354–1367
  117. Nordoy A, et al. Effect of omega-3 fatty acids and simvastatin on hemostatic risk factors and postprandial hyperlipemia in patients with combined hyperlipemia. Arterioscler Thromb Vasc Biol. 2000;20(1):259–265
  118. Meyer BJ, et al. Dose-dependent effects of docosahexaenoic acid supplementation on blood lipids in statin-treated hyperlipidaemic subjects. Lipids. 2007;42(2):109–115
  119. Mackness MI, et al. Effects of a new fish oil concentrate on plasma lipids and lipoproteins in patients with hypertriglyceridaemia. Eur J Clin Nutr. 1994;48(12):859–865
  120. Downs JR, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998;279(20):1615–1622
  121. Sacks FM, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996;335(14):1001–1009
  122. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339(19):1349–1357
  123. Miettinen TA, et al. Serum, biliary, and fecal cholesterol and plant sterols in colectomized patients before and during consumption of stanol ester margarine. Am J Clin Nutr. 2000;71(5):1095–1102
  124. Barzi F, et al. A comparison of lipid variables as predictors of cardiovascular disease in the Asia pacific region. Ann Epidemiol. 2005;15:405–413
  125. Robinson JG, Stone NJ. Identifying patients for aggressive cholesterol lowering: the risk curve concept. Am J Cardiol. 2006;98(10):1405–1408
  126. De Caterina R, Basta G. n-3 Fatty acids and the inflammatory response — biological background. Eur Heart J Suppl. 2001;3(suppl D):D42–D49
  127. Marchioli R, et al. Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-Prevenzione. Circulation. 2002;105(16):1897–1903
  128. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation. 2003;107:363–369
  129. Yusuf S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364(9438):937–952
  130. Mattson FH, Volpenhein RA, Erickson BA. Effect of plant sterol esters on the absorption of dietary cholesterol. J Nutr. 1977;107(7):1139–1146
  131. Mattson FH, Grundy SM, Crouse JR. Optimizing the effect of plant sterols on cholesterol absorption in man. Am J Clin Nutr. 1982;35(4):697–700
  132. Jandacek RJ, Webb MR, Mattson FH. Effect of an aqueous phase on the solubility of cholesterol in an oil phase. J Lipid Res. 1977;18(2):203–210
  133. Rasmussen HE, et al. Reduction in cholesterol absorption is enhanced by stearate-enriched plant sterol esters in hamsters. J Nutr. 2006;136(11):2722–2727
  134. Ewart HS, et al. Fish oil containing phytosterol esters alters blood lipid profiles and left ventricle generation of thromboxane a(2) in adult guinea pigs. J Nutr. 2002;132(6):1149–1152
  135. Russell JC, et al. Improvement of vascular dysfunction and blood lipids of insulin-resistant rats by a marine oil-based phytosterol compound. Lipids. 2002;37(2):147–152
  136. Demonty I, et al. Fish-oil esters of plant sterols improve the lipid profile of dyslipidemic subjects more than do fish-oil or sunflower oil esters of plant sterols. Am J Clin Nutr. 2006;84(6):1534–1542
  137. Katan MB, Grundy S, Jones PJ. Efficacy and safety of plant stanols and sterols in the management of blood cholesterol levels. Mayo Clin Proc. 2003;78:965–978
  138. Berger A, Jones PJ, Abumweis SS. Plant sterols: factors affecting their efficacy and safety as functional food ingredients. Lipids Health Dis. 2004;3:5
  139. Acuff RV, et al. The lipid lowering effect of plant sterol ester capsules in hypercholesterolemic subjects. Lipids Health Dis. 2007;6:11
  140. Earnest CP, et al. Examination of encapsulated phytosterol ester supplementation on lipid indices associated with cardiovascular disease. Nutrition. 2007;23(9):625–633
  141. Jones PJ, et al. Fish-oil esters of plant sterols differ from vegetable-oil sterol esters in triglycerides lowering, carotenoid bioavailability and impact on plasminogen activator inhibitor-1 (PAI-1) concentrations in hypercholesterolemic subjects. Lipids Health Dis. 2007;6:28
  142. Micallef MA, Garg ML. The lipid-lowering effects of phytosterols and (n-3) polyunsaturated fatty acids are synergistic and complementary in hyperlipidemic men and women. J Nutr. 2008;138(6):1086–1090
  143. Micallef MA, Garg ML. Anti-inflammatory and cardioprotective effects of n-3 polyunsaturated fatty acids and plant sterols in hyperlipidemic individuals. Atherosclerosis. 2008;
  144. Caslake MJ, et al. Effect of sex and genotype on cardiovascular biomarker response to fish oils: the FINGEN Study. Am J Clin Nutr. 2008;88(3):618–629

PII: S0955-2863(09)00135-1

doi: 10.1016/j.jnutbio.2009.06.009

The Journal of Nutritional Biochemistry
Volume 20, Issue 12 , Pages 927-939 , December 2009

Article Tools

* Image Usage & Resolution